Aurobindo Pharma Q1 Net up 24 per cent at Rs 585 crore

By: |
New Delhi | Published: August 23, 2016 9:12:33 PM

Drug firm Aurobindo Pharma reported a 23.81 per cent rise in consolidated net profit to Rs 584.96 crore for the first quarter ended June 30, 2016, mainly on account of robust sales.

Vaccines segment is another addition to the company's differentiated portfolio where there are unmet needs and limited competition, Aurobindo Pharma said in its annual report. (Source: Website)The company had posted a net profit after taxes, minority interest and share of profit of joint ventures of Rs 472.45 crore for the corresponding period of the previous fiscal, Aurobindo Pharma said in a filing to BSE. (Source: Website)

Drug firm Aurobindo Pharma today reported a 23.81 per cent rise in consolidated net profit to Rs 584.96 crore for the first quarter ended June 30, 2016, mainly on account of robust sales.

The company had posted a net profit after taxes, minority interest and share of profit of joint ventures of Rs 472.45 crore for the corresponding period of the previous fiscal, Aurobindo Pharma said in a filing to BSE.

Consolidated total income from operations also rose to Rs 3,725.90 crore for the quarter under consideration as against Rs 3,298.93 crore for the same period a year ago.

Shares of Aurobindo Pharma today closed at Rs 736.30 per scrip on BSE, down 1.84 per cent from its previous close.

Commenting on the results, Aurobindo Pharma MD N Govindarajan, said: “The quarter started with a double digit growth year on year on the back of overall business performance. With focus on execution and capability enhancements we continue to progress on specialty generics for a sustained long term growth.”

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.